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Colonization of gastric mucosa by Helicobacter pylori is 
considered to be the cause of chronic gastritis, a strong 
risk factor for peptic ulcer disease and gastric cancer [l]. 
Several clinical trials have shown that bacterial eradica- 
tion considerably reduces the long-term recurrences of 
peptic ulcer and that it also induces a regression of 
primary low-grade B-cell gastric lymphoma. Eradication 
of H. pylori from the gastric mucosa is difficult, owing 
to the ecological habitat of the organism, which resides 
within and below the layer of mucus adherent to 
the gastric epithelial cells. Primary and acquired anti- 
microbial drug resistance has appeared as an important 
cause of treatment failure [2]. Current anti-H. pylori 
treatment regimens are based on the association of 
an antisecretory drug (proton pump inhibitor or H2 
receptor antagonist) with two antibiotics: clarithromycin 
associated with amoxycillin or an iinidazole derivative, 
e.g. metronidazole or tinidazole 131. 
The prevalence rate of resistance to metronidazole 
has been found to vary appreciably between different 
populations and ethnic groups, from <lo% up to 80% 
(2,4-61. Recently, resistance to clarithromycin has also 
been reported from different centers in Europe and in 
USA, but at a much lower frequency [2,4-61. 
The aim of this study was to determine the level 
of antimicrobial drug resistance in clinical isolates of 
H .  pylori collected in WrocYaw, Poland from 1994 to 
1995. 
University of Medicine, Wroclaw, Poland. Bacterial 
isolates recovered after treatment failure were not in- 
cluded in this study. 
Primary isolation was performed on Columbia agar 
with 10% horse blood containing Dent’s selective supple- 
ment S R  147 (Oxoid, Basingstoke, UK). The isolates 
were subsequently stored in sterile defibrinated horse 
blood at -80°C. Prior to testing, the isolates were sub- 
cultured twice on Columbia agar with 10% horse blood 
in a micro-aerobic atmosphere (5% 0 2 ,  10%) CO?, 85% 
Nz). Colonies from agar plates were scraped and then 
suspended in 2 mL of brucella broth. 
Minimal inhibitory concentrations (MICs) were 
determined by an agar dilution method. We used 
Columbia agar supplemented with 10% horse blood 
and metronidazole, clarithroniycin and erythromycin 
in two-fold dilutions ranging from 0.06 to 32 mg/L. 
Amoxycillin was diluted from 0.008 to 1 nig/L. A 
multipoint Steers replicator apparatus delivering 4 pL 
of the prepared bacterial suspension (final inoculuin of 
? lo5 CFU/spot) was used to inoculate the surface of 
the agar plates. MICs were read after 3-5 days of 
incubation at  37°C in a micro-aerobic atmosphere. 
MICs of >2  mg/L for clarithromycin and erythro- 
mycin and >8 mg/L for nietronidazole were considered 
to indicate resistance. 
Fisher’s exact test was used to make statistical 
comparisons between patient groups. P values of 10.05 
were considered to be significant 
MATERIALS AND METHODS 
RESULTS 
Strains from 58 H .  pylori-positive patients (36 from 
children, 22 from adults) were randomly selected from 
the collection of the Department of Microbiology, 
Table 1 shows the MIC values of the four investigated 
antiniicrobial agents for the 58 H. pylori  strains that 
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Table 1 In vitro activity of four antimicrobial agents 
against H. pylori 
the treatment of gynecologic infections or for the 
therapy of intestinal parasitic infections has been 
suggested to contribute to a high rate of resistance [7]. Antimicrobial MIC (mg/L) % 
agents M I G O  M I C ~ O  Range Resistance Yousfy et a1 [9] showed that triple therapy with 
omeprazole, clarithromycin and metronidazole gave a 
Clarithromvcin 0.125 0.5 0.06-32 12 high eradication rate in patients who had previously 
Amoxycillin 0.03 0.125 0.008-0.250 0 
Erythromycin 0.5 2 0.06-32 12 
Metronidazole 8 32 0.06-32 45 
were isolated in Poland. Amoxycillin had MICs for 
90% of the strains (MIC90) of less than 0.125 mg/L. 
The MIC5o and MIC9o values of clarithromycin were 
0.125 mg/L and 0.5 mg/L, respectively. Erythromycin 
had MICso and MIC90 values of 0.5 mg/L and 2 mg/L, 
respectively. Metronidazole had a moderate activity, 
with MIC5o 8 mg/L and MIC9o 32 mg/L. Resistance 
to metronidazole (MIC >8 mg/L) was found in 26 
strains (45%), while clarithromycin and erythromycin 
resistance (MIC >2  mg/L) occurred in seven strains 
(12%). None of the strains was found to be resistant to 
amoxycillin. 
The rate of metronidazole resistance was signi- 
ficantly higher ( ~ ~ 0 . 0 5 )  in females than in males (56% 
versus 31%), while no such difference was observed 
for clarithromycin. Likewise, there were no significant 
differences in antimicrobial resistance rates in relation 
to age groups, although a trend towards a higher 
frequency of resistance to clarithromycin was found to 
occur in children. Six of 36 (16.6%) versus 1 of 22 
(4.5%) in adults. Five of the 58 strains were found 
to be resistant to metronidazole, clarithromycin and 
erythromycin. 
DISCUSSION 
The efficacy of the treatment of gastric infection caused 
by H. pylori can be reduced by the occurrence of 
primary or acquired resistance to various drugs, 
especially metronidazole [7]. This has made suscepti- 
bility testing of H. pylori increasingly important in the 
search for efficient antimicrobial combinations that 
allow for the eradication of this bacterium from the 
stomach. However, until now the methods proposed 
for in vitro susceptibility testing of H. pylori have 
suffered from a lack of standardization. In most studies 
[2,7,8], including this report, the agar dilution method 
and/or the Etest have been used. 
In this study, we found that 45% of all H .  pylori 
isolates were resistant to metronidazole. The rate of 
resistance to metronidazole was significantly higher 
(p=0.05) in females than in males (56% versus 31%). 
The more frequent use of nitromidazole in women for 
failed antimicrobial therapy. It is claimed that this 
combination was also effective for those harboring 
strains resistant to metronidazole, but not for strains 
resistant to both metronidazole and clarithromycin. In 
our study, four patients whose strains exhibited resistance 
to both metronidazole and clarithromycin failed therapy. 
Standard triple therapy for H .  pylori using metro- 
nidazole with amoxycillin or tetracycline and bismuth 
salts has been shown to be less effective in patients 
with a metronidazole-resistant strain [ 101. Resistance 
to nitromidazole has been observed worldwide and 
presently occurs quite commonly in several countries. 
For instance, metronidazole-resistant strains were found 
in 27% of patients in Ireland, in 41% of patients in The 
Netherlands and in 61% of patients in Peru before their 
first anti-H. pylori treatment [5-71. Among H. pylori 
strains isolated in Poland, 46-69% were found to be 
resistant to metronidazole, 20% to erythromycin and 
5% to clarithromycin [2,4] 
Pre-treatment clarithromycin resistance in the UK 
is less than 3% [ l l ] ,  and in Italy it is 6% [8]. However, 
in France the prevalence of clarithromycin resistance 
may be as high as 15% [12]. 
In this study, resistance to clarithromycin was 
found in 12% of the examined strains. Resistance of 
H. pylori to clarithromycin has been reported for the 
first time in Poland among untreated patients and was 
found to occur not uncommonly, especially in the 
pediatric population. The high rates of primary nitro- 
midazole and macrolide resistance in selected sub- 
groups probably reflect the use of these drugs for 
treating unrelated infections in the community. 
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Anaerobes are well-established human pathogens, 
especially in hosts whose normal body defenses are 
lowered by surgery, trauma, malnutrition and malig- 
nancies. Even though the contribution of Bacteroides 
jaj$is to the composition of normal anaerobic bacterial 
microbiota of the body is relatively small, it is 
paradoxically the most common anaerobic pathogen 
encountered in major human infections, in particular 
infections involving hollow organs and soft tissues. It is 
also clinically important because of its growing rate of 
resistance to a number of available antibiotics. Periodic 
determination of susceptibility of B. fragilis would 
therefore be useful in guiding the selection of empirical 
antibiotic therapy of mixed infections involving this 
clinically important anaerobic pathogen 11,2]. 
Data generated from various nationwide surveil- 
lance studies of the susceptibility of B. f r q i l i s  to a 
variety of antibiotics in the USA [3,4], Europe [5,6] 
and Japan [7] have been published. So far, surveys of 
antibiotic susceptibility of B. frugilis have not been 
conducted in Kuwait. Because of the lack of published 
data on the efficacy of these agents against anaerobes in 
Kuwait, an evaluation of their in vitro activity against 
clinical isolates of B. f r q i l i s  was undertaken in the two 
largest hospitals in the country. 
Pure powders of the five antibiotic5 were used in 
this study: piperacillin and piperacillin/tazobactam 
(Wyeth-Ayerst, Kuwait), anioxycillin/clavulanic acid 
(SniithKline Beecham Pharm., Kuwait), meropeneni 
(Zeneca, Kuwait) and imipeneni (MSD, Kuwait). Two 
hundred and twenty-one consecutive fresh isolates of 
B.frugilis sensu strict0 were studied. They were isolated 
from intra-abdominal and pelvic abscesses (198 isolates), 
post-intra-abdominal surgical wound infections (1 5 
isolates) and blood cultures (eight isolates) over a period 
of 18 months, April 1996 to December 1997, in the 
microbiology laboratories of the two hospitals. The 
isolates were identified in our Anaerobe Research 
Laboratory by conventional methods using a battery of 
biochemical and fermentation tests and confirmed by 
the Vitek Anaerobic Card System (Bio-Merieux Vitek 
Inc., Hazelwood, MO, USA). 
Minimum inhibitory concentrations (MICs) of the 
antibiotics were determined by the agar dilution 
